As we head towards the Labor Day holiday weekend the market performance of the sector's blue chip companies have so far failed to capitalize on their welcomed surge in valuation in July. As a result they are treading water this month with the value of the BioWorld Biopharmaceutical Index up a modest 0.5 percent at last Thursday's market close compared to a 1 percent increase in the Dow Jones Industrial Average and a 3 percent jump in value for the Nasdaq Composite index. Read More
The biopharma sector's research and development investments are continuing to increase. An in-depth analysis by BioWorld Insight of the second-quarter 2018 financial reports from the top 100 public biopharmaceutical companies by market cap, excluding big pharma companies, found that collectively they invested over 22 percent more in R&D during the first two quarters of 2018 than they did in the comparable period last year. A whopping $19.2 billion has so far been spent compared to $15.7 billion last year. Read More
